IN PEDIATRIC PATIENTS WITH EPISODIC MIGRAINE 6–17 YEARS OF AGE, WHO WEIGH ≥45 KG,

AJOVY IS THE FIRST AND ONLY ANTI-CGRP INJECTION APPROVED FOR PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN PEDIATRIC PATIENTS^1-3

JUMP TO TOPICS BELOW:

Pediatric efficacy

Pediatric safety results

Pediatric once-monthly dosing

Pediatric patients saw a significant reduction in monthly migraine days with AJOVY vs placebo in the pediatric EM trial¹*

PRIMARY ENDPOINT¹

Pediatric patients randomized to monthly dosing had a mean baseline of 7.8 migraine days per month and experienced, on average:

2.5

FEWER MIGRAINE DAYS

at month 3 vs 1.4

with placebo (P<0.021)

SECONDARY ENDPOINT¹

≥50^%

REDUCTION

in monthly number of migraine days with
monthly dosing

47.2% on AJOVY vs 27%

on placebo (P<0.002)

AJOVY for pediatric patients has a safety profile consistent with that observed in the adult population¹

The most common adverse reactions for AJOVY observed in the pediatric EM trial were injection-site reactions,^† similar to the overall safety profile observed in long-term adult clinical studies¹

^†Injection-site reactions include multiple related adverse event terms, such as injection-site erythema, swelling, and pain.

For all your eligible adult and pediatric patients, there’s no difference in once-monthly dosing or coverage

ONCE-MONTHLY DOSE

for pediatric patients is the same as the monthly dose for adults

MONTHLY

AJOVY 225 mg/1.5 mL autoinjector

Sig: 225 mg subcutaneous (1 autoinjector)
every month

Dis: 1.5 mL

Refills: 11

94% commercial lives covered⁴

Eligible commercially insured patients may save on each monthly prescription of AJOVY^‡ with the AJOVY Savings Card

Check your local coverage with our formulary tool

See coverage

Contraindications: AJOVY® is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting.

Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.

AJOVY should be discontinued if signs or symptoms of Raynaud’s phenomenon develop. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

AJOVY is indicated for:

The preventive treatment of migraine in adults, and
The preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.

Please see the full Prescribing Information.

CGRP: calcitonin gene-related peptide; EM: episodic migraine.

*Pediatric EM trial design: AJOVY was evaluated in a phase 3 multicenter, randomized, double-blind, placebocontrolled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous administration of AJOVY (n=123) vs placebo (n=111^§) over a 12-week period for the preventive treatment of episodic migraine (<15 headache days per month) in 235 pediatric patients aged 6 to 17 years. The primary efficacy endpoint was the mean change from baseline in the monthly average number of migraine days during the 3-month treatment period. Secondary endpoints included the proportion of patients reaching ≥50% reduction in monthly average number of migraine days during the 3-month treatment period, the mean change from baseline in the monthly average number of days of use of any acute headache medication during the 3-month treatment period, and the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.

^‡Out-of-pocket costs may vary based on insurance coverage. Exclusions and limitations apply. Please note, this offer is not available for patients eligible for Medicare, Medicaid, or any other public payer coverage. See full Terms and Conditions for eligibility and restrictions.

^§One patient in the placebo group was excluded from the analysis due to not having at least 10 days of postbaseline efficacy data.

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Aimovig® (erenumab-aooe) injection. Prescribing Information. Thousand Oaks, CA: Amgen Inc. 3. Emgality® (galcanezumab-gnlm) injection. Prescribing Information. Indianapolis, IN. Lilly USA, LLC. 4. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.

AJOVY IS THE FIRST AND ONLY ANTI-CGRP INJECTION APPROVED FOR PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN PEDIATRIC PATIENTS1-3

Pediatric patients saw a significant reduction in monthly migraine days with AJOVY vs placebo in the pediatric EM trial1*

PRIMARY ENDPOINT1

SECONDARY ENDPOINT1

AJOVY for pediatric patients has a safety profile consistent with that observed in the adult population1